{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:33:21Z","timestamp":1792528401410,"version":"4.5.0"},"reference-count":123,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Glioblastoma (GBM) remains one of the most lethal primary brain tumors, with limited therapeutic improvement despite maximal surgical resection, radiotherapy, and temozolomide. A major barrier to durable treatment response is the profoundly immunosuppressive tumor microenvironment, which is characterized by immune exclusion, defective antigen presentation, myeloid dominance, and severe T-cell dysfunction. Tumor-associated macrophages, resident microglia, myeloid-derived suppressor cells, neutrophils, regulatory T cells, and glioma-derived extracellular vesicles collectively establish a suppressive niche through cytokine signaling, metabolic restriction, checkpoint ligand expression, impaired phagocytosis, and extracellular matrix remodeling. Key pathways, including TGF-\u03b2\/SMAD, IL-10\/STAT3, IDO\u2013kynurenine metabolism, arginase-1-mediated amino acid depletion, adenosine signaling, hypoxia\u2013HIF-1\u03b1 activation, and VEGF-driven vascular dysfunction, converge to prevent effective antitumor immunity. This review summarizes the cellular and molecular mechanisms underlying immune suppression in GBM and discusses emerging therapeutic strategies, including myeloid reprogramming, phagocytosis checkpoint blockade, neutrophil and NET targeting, cellular immunotherapy, checkpoint blockade combinations, and metabolic intervention. Understanding these interconnected barriers may guide rational multimodal strategies to convert immune-excluded GBM into immune-responsive disease.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1806996","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:35:08Z","timestamp":1782970508000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The immunosuppressive tumor microenvironment in glioblastoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Jing","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine, Guangyuan Central Hospital","place":["Guangyuan, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Guangyuan Central Hospital","place":["Guangyuan, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Jin","sequence":"additional","affiliation":[{"name":"Scientific Research and Innovation Center, Guangyuan Central Hospital","place":["Guangyuan, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Lu","sequence":"additional","affiliation":[{"name":"Scientific Research and Innovation Center, Guangyuan Central Hospital","place":["Guangyuan, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Guangyuan Central Hospital","place":["Guangyuan, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910570","article-title":"Review of novel surgical, radiation, and systemic therapies and clinical trials in glioblastoma","volume":"25","author":"Valerius","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41392-025-02299-4","article-title":"Glioblastoma at the crossroads: current understanding and future therapeutic horizons","volume":"10","author":"Singh","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-025-02937-9","article-title":"Spatial transcriptomic analysis reveals lack of response to PD-1 blockade in recurrent glioblastoma","volume":"150","author":"Artzi","year":"2025","journal-title":"Acta Neuropathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-4255559\/v1","article-title":"Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma","volume":"31","author":"Long","year":"2025","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.770561","article-title":"Immunosuppression in glioblastoma: current understanding and therapeutic implications","volume":"11","author":"Himes","year":"2021","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020263","article-title":"Resistance mechanisms and barriers to successful immunotherapy for treating glioblastoma","volume":"9","author":"Adhikaree","year":"2020","journal-title":"Cells"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1044544","article-title":"The immune landscape of high-grade brain tumor after treatment with immune checkpoint blockade","volume":"13","author":"Park","year":"2022","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.009","article-title":"The microenvironmental landscape of brain tumors","volume":"31","author":"Quail","year":"2017","journal-title":"Cancer Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma","volume":"15","author":"Lim","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01713","article-title":"Microenvironmental regulation of tumor progression and therapeutic response in brain metastasis","volume":"10","author":"Schulz","year":"2019","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"494","DOI":"10.20944\/preprints202502.1189.v1","article-title":"Therapeutic targets in glioblastoma: molecular pathways, emerging strategies, and future directions","volume":"14","author":"Tang","year":"2025","journal-title":"Cells"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.32604\/or.2024.052130","article-title":"Hypoxia-inducible factor 1alpha and vascular endothelial growth factor in glioblastoma multiforme: a systematic review going beyond pathologic implications","volume":"32","author":"Vageli","year":"2024","journal-title":"Oncol Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1384249","article-title":"Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments","volume":"15","author":"Feldman","year":"2024","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020265","article-title":"Immunotherapy of glioblastoma: current strategies and challenges in tumor model development","volume":"10","author":"Majc","year":"2021","journal-title":"Cells"},{"key":"B15","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/cac2.70016","article-title":"Blocking ITGA5 potentiates the efficacy of anti-PD-1 therapy on glioblastoma by remodeling tumor-associated macrophages","volume":"45","author":"Zhao","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.1038\/s41467-023-39683-z","article-title":"Oncolytic viruses engineered to enforce cholesterol efflux restore tumor-associated macrophage phagocytosis and anti-tumor immunity in glioblastoma","volume":"14","author":"Wang","year":"2023","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41698-025-00920-x","article-title":"Exploring tumor-associated macrophages in glioblastoma: from diversity to therapy","volume":"9","author":"Zhao","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1238233","article-title":"The diversity and dynamics of tumor-associated macrophages in recurrent glioblastoma","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13073-023-01207-1","article-title":"Spatially resolved transcriptomic profiles reveal unique defining molecular features of infiltrative 5ALA-metabolizing cells associated with glioblastoma recurrence","volume":"15","author":"Andrieux","year":"2023","journal-title":"Genome Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40478-024-01769-0","article-title":"Spatial transcriptomics reveals segregation of tumor cell states in glioblastoma and marked immunosuppression within the perinecrotic niche","volume":"12","author":"Liu","year":"2024","journal-title":"Acta Neuropathol Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4185","article-title":"The role of microglia and macrophages in glioma maintenance and progression","volume":"19","author":"Hambardzumyan","year":"2016","journal-title":"Nat Neurosci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1632122","article-title":"Interactions between glioblastoma and myeloid cells","volume":"13","author":"Li","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0312764","article-title":"Single-cell transcriptomics reveals immunosuppressive microenvironment and highlights tumor-promoting macrophage cells in glioblastoma","volume":"20","author":"Cheng","year":"2025","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-19-0240","article-title":"Myeloid-derived suppressive cells promote B cell-mediated immunosuppression via transfer of PD-L1 in glioblastoma","volume":"7","author":"Lee-Chang","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113109","article-title":"Quantitative analysis of immune cells within the tumor microenvironment of glioblastoma and their relevance for prognosis","volume":"142","author":"Wang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0313-5","article-title":"VISTA expressed in tumour cells regulates T cell function","volume":"120","author":"Mulati","year":"2019","journal-title":"Br J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112074","article-title":"PD-1\/PD-L1 axis is involved in the interaction between microglial polarization and glioma","volume":"133","author":"Wang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.immuni.2026.03.010","article-title":"Microglia-glioblastoma crosstalk mediates glioblastoma invasion at the far infiltration zone","volume":"59","author":"Nebeling","year":"2026","journal-title":"Immunity"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13040542","article-title":"Exploring monocytes-macrophages in immune microenvironment of glioblastoma for the design of novel therapeutic strategies","volume":"13","author":"Caverz\u00e1n","year":"2023","journal-title":"Brain Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cimb46080462","article-title":"Phagocytosis checkpoints in glioblastoma: CD47 and beyond","volume":"46","author":"Afzal","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01671-2","article-title":"CD47 masks pro-phagocytic ligands in cis on tumor cells to suppress antitumor immunity","volume":"24","author":"Tang","year":"2023","journal-title":"Nat Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.05.046","article-title":"Reduced Malignant glioblastoma recurrence post-resection through the anti-CD47 antibody and temozolomide co-embedded in-situ hydrogel system","volume":"359","author":"Ye","year":"2023","journal-title":"J Control Release"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/cells10010018","article-title":"Myeloid cells in glioblastoma microenvironment","volume":"10","author":"De Leo","year":"2020","journal-title":"Cells"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041042","article-title":"Tumor microenvironment in gliomas: a treatment hurdle or an opportunity to grab","volume":"15","author":"Di Nunno","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.631037","article-title":"Genetic alterations in gliomas remodel the tumor immune microenvironment and impact immune-mediated therapies","volume":"11","author":"Garcia-Fabiani","year":"2021","journal-title":"Front Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0095-6","article-title":"Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate","volume":"24","author":"Bunse","year":"2018","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051319","article-title":"Tumor-associated macrophages in gliomas-basic insights and treatment opportunities","volume":"14","author":"Andersen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13657","article-title":"Microglia and macrophages in glioblastoma: landscapes and treatment directions","volume":"18","author":"Solomou","year":"2024","journal-title":"Mol Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s11033-026-11525-3","article-title":"Neutrophils in glioblastoma: orchestrators of the tumor microenvironment and immune evasion","volume":"53","author":"Demir","year":"2026","journal-title":"Mol Biol Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.994698","article-title":"Myeloidcells in the immunosuppressive microenvironment in glioblastoma: the characteristics and therapeutic strategies","volume":"14","author":"Huang","year":"2023","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"151853","DOI":"10.1016\/j.imbio.2019.10.002","article-title":"Role of myeloid cells in the immunosuppressive microenvironment in gliomas","volume":"225","author":"Locarno","year":"2020","journal-title":"Immunobiology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12957-019-1686-5","article-title":"Prognostic impact of neutrophil-to-lymphocyte ratio in gliomas: a systematic review and meta-analysis","volume":"17","author":"Lei","year":"2019","journal-title":"World J Surg Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"10971","DOI":"10.1038\/s41467-025-65933-3","article-title":"Inhibiting the formation of neutrophil extracellular traps to prevent the recurrence of post-operative glioblastoma","volume":"16","author":"Han","year":"2025","journal-title":"Nat Commun"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28551","article-title":"CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-\u03b2","volume":"134","author":"Jablonska","year":"2014","journal-title":"Int J Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12885-025-14698-5","article-title":"CXCL8-dependent recruitment of neutrophils by the tumor microenvironment drives poor prognosis in glioblastoma patients","volume":"26","author":"Wang","year":"2025","journal-title":"BMC Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.152706","article-title":"Single-cell mapping of TMZ-resistant glioma reveals CXCL2\/3-CXCR2-associated neutrophil communication","volume":"785","author":"Wan","year":"2025","journal-title":"Biochem Biophys Res Commun"},{"key":"B47","doi-asserted-by":"publisher","first-page":"6992","DOI":"10.1158\/1078-0432.ccr-11-1107","article-title":"Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I","volume":"17","author":"Sippel","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"47","DOI":"10.15698\/cst2019.02.176","article-title":"Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastoma","volume":"3","author":"Won","year":"2019","journal-title":"Cell Stress"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2019.0353","article-title":"Neutrophil extracellular traps mediate the crosstalk between glioma progression and the tumor microenvironment via the HMGB1\/RAGE\/IL-8 axis","volume":"17","author":"Zha","year":"2020","journal-title":"Cancer Biol Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1186\/s12964-025-02458-8","article-title":"Neutrophils and neutrophil extracellular traps: double-edged swords in cancer pathophysiology and therapy resistance","volume":"23","author":"Shen","year":"2025","journal-title":"Cell Commun Signal"},{"key":"B51","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1158\/0008-5472.can-24-3393","article-title":"Surgery-induced neutrophil extracellular traps promote tumor metastasis by reprogramming cancer cell lipid metabolism","volume":"85","author":"Haykal","year":"2025","journal-title":"Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-23-0913","article-title":"Glioblastoma-infiltrating CD8+ T cells are predominantly a clonally expanded GZMK+ effector population","volume":"14","author":"Wang","year":"2024","journal-title":"Cancer Discov"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27329","article-title":"Tumor-infiltrating CD8(+) sub-populations in primary and recurrent glioblastoma: An in-silico study","volume":"10","author":"Abdoli Shadbad","year":"2024","journal-title":"Heliyon"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1236824","article-title":"The immune cell landscape of glioblastoma patients highlights a myeloid-enriched and immune suppressed microenvironment compared to metastatic brain tumors","volume":"14","author":"Musca","year":"2023","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072024","article-title":"The glioma immune landscape: A double-edged sword for treatment regimens","volume":"15","author":"Mahajan","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1097\/wco.0000000000000988","article-title":"T cell dysfunction in glioblastoma: a barrier and an opportunity for the development of successful immunotherapies","volume":"34","author":"Jansen","year":"2021","journal-title":"Curr Opin Neurol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.179853","article-title":"Spatial analysis of recurrent glioblastoma reveals perivascular niche organization","volume":"9","author":"Onubogu","year":"2024","journal-title":"JCI Insight"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf236","article-title":"T cell immunity in glioma and potential implications for immunotherapy: A systematic review","volume":"28","author":"Luning","year":"2026","journal-title":"Neuro Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.993444","article-title":"Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2+\/CX3CR1+ M-MDSCs into the tumor microenvironment in a redundant manner","volume":"13","author":"Takacs","year":"2023"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-16-0144","article-title":"CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells","volume":"76","author":"Chang","year":"2016","journal-title":"Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-024-01544-7","article-title":"Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives","volume":"17","author":"Lin","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2147\/jir.s341981","article-title":"CTLA4-mediated immunosuppression in glioblastoma is associated with the infiltration of macrophages in the tumor microenvironment","volume":"14","author":"Guan","year":"2021","journal-title":"J Inflammation Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050817","article-title":"Immune cell interplay in the fight against GBM","volume":"17","author":"Vallieri","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B65","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s40425-019-0719-5","article-title":"Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8(+) T cells","volume":"7","author":"Mastelic-Gavillet","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-018-0227-9","article-title":"CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature","volume":"21","author":"Louveau","year":"2018","journal-title":"Nat Neurosci"},{"key":"B67","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ijrobp.2021.07.1598","article-title":"Systematic review and pooled analysis of the impact of treatment-induced lymphopenia on survival of glioblastoma patients","volume":"19","author":"Saeed","year":"2024","journal-title":"Radiat Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn6758","article-title":"Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma","volume":"15","author":"Ghosh","year":"2023"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac087","article-title":"The effect of dexamethasone on the microenvironment and efficacy of checkpoint inhibitors in glioblastoma: a systematic review","volume":"4","author":"Swildens","year":"2022","journal-title":"Neuro-Oncology Adv"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-2291","article-title":"Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma","volume":"27","author":"Iorgulescu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122904","article-title":"Amplifying glioblastoma immunotherapy: T cell shielding through nitric oxide\/reactive oxygen species scavenging nanoparticles potentiates anti-PD-1","volume":"315","author":"Lee","year":"2025","journal-title":"Biomaterials"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2021.105472","article-title":"TIGIT\/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells","volume":"121","author":"Mao","year":"2021","journal-title":"Oral Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-024-01602-0","article-title":"Redefining chimeric antigen receptor T-cell (CAR-T) regulation: China\u2019s responses to address secondary cancer risks of CAR-T therapy","volume":"17","author":"Tan","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105141","article-title":"TGF-\u03b2-mediated suppression of NK cell function and targeting strategies in tumor immunotherapy","volume":"219","author":"Wang","year":"2026","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25021067","article-title":"The TGF-\u03b2 family in glioblastoma","volume":"25","author":"Gol\u00e1n-Cancela","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B76","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41467-022-28523-1","article-title":"T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10","volume":"13","author":"Ravi","year":"2022","journal-title":"Nat Commun"},{"key":"B77","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/metabo16030185","article-title":"Nexus of IDO1\/Kynurenine pathway to T-cell exhaustion: Hypoxia-induced tryptophan metabolism in glioblastoma","volume":"16","author":"Abikenari","year":"2026"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101168","article-title":"Absence of Lugol staining indicates initiation of esophageal squamous cell carcinoma: A combined genomic and epidemiologic study","volume":"4","author":"Liu","year":"2023","journal-title":"Cell Rep Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1186\/s12885-023-11069-w","article-title":"Glioma angiogenesis is boosted by ELK3 activating the HIF-1\u03b1\/VEGF-A signaling axis","volume":"23","author":"Yueyang","year":"2023","journal-title":"BMC Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.semcancer.2024.04.003","article-title":"Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools","volume":"101","author":"Cela","year":"2024","journal-title":"Semin Cancer Biol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.vesic.2025.100075","article-title":"Role of extracellular vesicles in immune modulation, angiogenesis, progression and therapeutic resistance of glioblastoma","volume":"5","author":"Izhar","year":"2025","journal-title":"Extracellular Vesicle"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.108807","article-title":"Glioblastoma extracellular vesicles modulate immune PD-L1 expression in accessory macrophages upon radiotherapy","volume":"27","author":"Schweiger","year":"2024","journal-title":"iScience"},{"key":"B83","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12964-024-01473-5","article-title":"Mutual regulation of PD-L1 immunosuppression between tumor-associated macrophages and tumor cells: a critical role for exosomes","volume":"22","author":"Wang","year":"2024","journal-title":"Cell Commun Signaling"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18081269","article-title":"Extracellular vesicle-associated miRNAs in glioblastoma: Mechanisms, biomarkers, therapies, and links to neurodegeneration","volume":"18","author":"Li","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.3390\/cancers16142500","article-title":"Glioma-stem-cell-derived exosomes remodeled glioma-associated macrophage via NEAT1\/miR-125a\/STAT3 pathway","volume":"16","author":"Pan","year":"2024"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab228","article-title":"Glioblastoma genetic drivers dictate the function of tumor-associated macrophages\/microglia and responses to CSF1R inhibition","volume":"24","author":"Rao","year":"2022","journal-title":"Neuro Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2011.00217","article-title":"Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling","volume":"18","author":"Coniglio","year":"2012","journal-title":"Mol Med"},{"key":"B88","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1186\/s12967-024-05301-9","article-title":"The tumour microenvironment, treatment resistance and recurrence in glioblastoma","volume":"22","author":"White","year":"2024","journal-title":"J Transl Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"9718","DOI":"10.1038\/s41467-024-54129-w","article-title":"Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRP\u03b3-derived CD47 blocker","volume":"15","author":"Martins","year":"2024","journal-title":"Nat Commun"},{"key":"B90","doi-asserted-by":"publisher","first-page":"viii153","DOI":"10.1093\/neuonc\/noae165.0600","article-title":"IMMU-07. The immune landscape of pediatric brain tumors: A transcriptomic analysis","volume":"26","author":"Frederico","year":"2024","journal-title":"Neuro-Oncology"},{"key":"B91","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1038\/s41467-026-70221-9","article-title":"Dual phagocytosis-checkpoint blockade revitalizes immune surveillance in mouse models of glioblastoma","volume":"17","author":"Ha","year":"2026","journal-title":"Nat Commun"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1584688","article-title":"Overcoming immunotherapy resistance in glioblastoma: challenges and emerging strategies","volume":"16","author":"Fu","year":"2025"},{"key":"B93","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/jitc-2020-sitc2020.0755","article-title":"CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity","volume":"52","author":"Teijeira","year":"2020","journal-title":"Immunity"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41467-023-37361-8","article-title":"Monocyte depletion enhances neutrophil influx and proneural to mesenchymal transition in glioblastoma","volume":"14","author":"Chen","year":"2023","journal-title":"Nat Commun"},{"key":"B95","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12974-024-03222-4","article-title":"Microenvironmental regulation of tumor-associated neutrophils in Malignant glioma: from mechanism to therapy","volume":"21","author":"Wen","year":"2024","journal-title":"J Neuroinflamm"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1135086","article-title":"Neutrophil extracellular traps in tumor progression and immunotherapy","volume":"14","author":"Yan","year":"2023"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115619","article-title":"Highly-tumor-targeted PAD4 inhibitors with PBA modification inhibit tumors in vivo by specifically inhibiting the PAD4-H3cit-NETs pathway in neutrophils","volume":"258","author":"Zhu","year":"2023","journal-title":"Eur J Med Chem"},{"key":"B98","article-title":"1520\u2005Phase I trial evaluating locoregionally-delivered IL13R\u03b12-targeting CAR T cells in high-grade glioma","volume":"11","author":"Brown","year":"2023"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03745-0","article-title":"Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial","volume":"31","author":"Bagley","year":"2025","journal-title":"Nat Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci Transl Med"},{"key":"B101","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12916-026-04783-2","article-title":"Myeloid-derived immunosuppression of chimeric antigen receptor T cells in the neuronal microenvironment of glioblastoma","volume":"24","author":"Zhang","year":"2026","journal-title":"BMC Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010249","article-title":"Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression","volume":"12","author":"Roerden","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2399141","article-title":"Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors","volume":"24","author":"Klampatsa","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"B104","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s13046-023-02815-w","article-title":"Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation","volume":"42","author":"Sun","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012321","article-title":"Envirotune-CAR-T: a hypoxia-responsive and glutamine-enhanced CAR-T cell therapy for overcoming tumor microenvironment-mediated suppression","volume":"13","author":"Li","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.ccell.2024.01.005","article-title":"The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1490911","article-title":"Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies","volume":"15","author":"Nolan-Stevaux","year":"2024"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012308","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM): current clinical insights, challenges, and future directions","volume":"13","author":"Walton","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032111","article-title":"Natural killer cell-based immunotherapy against glioblastoma","volume":"24","author":"Morimoto","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B110","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/s42003-022-03402-z","article-title":"Infiltrating natural killer cells bind, lyse and increase chemotherapy efficacy in glioblastoma stem-like tumorospheres","volume":"5","author":"Breznik","year":"2022","journal-title":"Commun Biol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdae174","article-title":"The landscape of immune checkpoint inhibitor clinical trials in glioblastoma: A systematic review","volume":"6","author":"Schonfeld","year":"2024","journal-title":"Neuro-Oncology Adv"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1057567","article-title":"Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier","volume":"14","author":"Frederico","year":"2023"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3390\/cells13131075","article-title":"Evaluation of the immunomodulatory effects of radiation for chimeric antigen receptor T cell therapy in glioblastoma multiforme","volume":"13","author":"Akhavan","year":"2024"},{"key":"B115","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1038\/s41467-024-48073-y","article-title":"TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in Malignant glioma: a randomized phase II Trial","volume":"15","author":"Everson","year":"2024","journal-title":"Nat Commun"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-019-03146-7","article-title":"Impact of overall corticosteroid exposure during chemoradiotherapy on lymphopenia and survival of glioblastoma patients","volume":"143","author":"Hui","year":"2019","journal-title":"J Neuro-Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2026.01.015","article-title":"Targeting immunosuppressive network in glioblastoma: Emerging strategies to overcome immunodeficiency and enhance therapeutic efficacy","volume":"16","author":"Zhou","year":"2026","journal-title":"Acta Pharm Sin B"},{"key":"B118","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s43046-026-00361-y","article-title":"Immune checkpoint crosstalk between LAG-3 and CD39\/CD73 in glioblastoma: dual-pathway regulation of metabolic exhaustion and therapeutic reversal strategies","volume":"38","author":"Mukherjee","year":"2026","journal-title":"J Egyptian Natl Cancer Institute"},{"key":"B119","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol Cancer"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104657","article-title":"Immunomodulatory mechanisms driving tumor escape in glioblastoma: The central role of IDO and tryptophan metabolism in local and systemic immunotolerance","volume":"209","author":"Gagliardi","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189343","article-title":"Targeting the kynurenine pathway in gliomas: Insights into pathogenesis, therapeutic targets, and clinical advances","volume":"1880","author":"Krupa","year":"2025","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1424396","article-title":"Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape","volume":"15","author":"Inocencio","year":"2024"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/s41467-024-44963-3","article-title":"Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1806996\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:35:10Z","timestamp":1782970510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1806996\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":123,"alternative-id":["10.3389\/fimmu.2026.1806996"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1806996","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"article-number":"1806996"}}